# US 2025/0122226 A1 · Glucose-sensitive albumin-binding derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0122226 A1
- Document ID: US20250122226A1
- Status: Published application
- Kind: A1
- Application number: 18/985,160
- Filed: 2024-12-18
- Published: 2025-04-17
- Earliest claimed: 2017-11-09
- Assignees: Novo Nordisk A/S
- Applicants: Novo Nordisk A/S
- Inventors: Thomas Kruse; Mikael Kofod-Hansen; Martin Werner Borchsenius Muenzel; Henning Thoegersen; Per Sauerberg; Jakob Ewald; Carsten Behrens; Thomas Hoeg-Jensen; Vojtech Balsanek; Zuzana Drobnakova; Ladislav Droz; Miroslav Havranek; Vladislav Kotek; Milan Stengl; Ivan Snajdr; Hana Drusanova
- Web page: https://patentgrep.com/patent/US20250122226A1

## CPC

- C07F 5/025: {Boronic and borinic acid compounds}
- A61K 31/69: Boron compounds
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- C12Q 1/00: Measuring or testing processes involving enzymes, nucleic acids or microorganisms (measuring or testing apparatus with condition measuring or sensing means, e.g. colony counters, C12M1/34); Compositions therefor; Processes of preparing such compositions
- C12Q 3/00: Condition responsive control processes (apparatus therefor C12M1/36; controlling or regulating in general G05)
- C40B 30/00: Methods of screening libraries
- C40B 30/04: by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- C40B 30/10: by measuring physical properties, e.g. mass
- G01N 24/088: {Assessment or manipulation of a chemical or biochemical reaction, e.g. verification whether a chemical reaction occurred or whether a ligand binds to a receptor in drug screening or assessing reaction kinetics}
- G01N 33/542: with steric inhibition or signal modification, e.g. fluorescent quenching
- G01N 33/66: involving blood sugars, e.g. galactose
- G01N 33/6827: {Total protein determination, e.g. albumin in urine}
- A61K 47/54: the modifying agent being an organic compound
- G01N 2333/76: Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.

## Claims

### Claim 1

A diboron compound comprising a structure of

### Claim 2 (depends on 1)

A diboron conjugate comprising the diboron compound of claim 1 and a drug substance, wherein the diboron compound is conjugated to the drug substance.

### Claim 3 (depends on 2)

The diboron conjugate of claim 2, wherein the drug substance is an insulin or an insulin analogue.

### Claim 4

The diboron compound (S)-2,3-Bis(1-hydroxy-4-(trifluoromethyl)-1,3-dihydrobenzo[c][1,2]oxaborole-6-carboxamido)propanoic acid of structure:

### Claim 5 (depends on 4)

A diboron conjugate comprising the diboron compound of claim 4 and a drug substance, wherein the diboron compound is conjugated to the drug substance via an optional linker by derivatisation of the carboxylic acid moiety of the diboron compound.

### Claim 6 (depends on 5)

The diboron conjugate of claim 5, wherein the drug substance is an insulin or an insulin analogue.

### Claim 7

An intermediate product 1-Hydroxy-4-(trifluoromethyl)-1,3-dihydrobenzo[c][1,2]oxaborole-6-carboxylic acid of structure:
